Stocks and Investing
Stocks and Investing
Fri, May 26, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Corinne Jenkins Maintained (BTAI) at Hold with Decreased Target to $25 on, May 26th, 2023
Corinne Jenkins of Goldman Sachs, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Decreased Target from $28 to $25 on, May 26th, 2023.
Corinne has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 1 agrees with Corinne's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
These are the ratings of the 3 analyists that currently disagree with Corinne
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $66 on, Wednesday, May 17th, 2023
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $40 on, Wednesday, May 10th, 2023
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023
Contributing Sources